AstraZeneca, Amgen’s Tezspire Succeeds in Phase 3 EoE Trial, Signaling Potential Label Expansion

AstraZeneca and Amgen said Tezspire met all primary and secondary endpoints in a phase 3 trial for eosinophilic esophagitis (EoE). The companies said they observed statistically significant and clinically meaningful improvements in measures of disease activity and severity and in symptoms at 24 weeks, with the effects maintained for 1 year. Tezspire generated more than $1 billion in sales for each company last year, while AstraZeneca reported $390 million in sales in the second quarter alone this year, a 45% increase from the same period a year earlier.